Recs
TMFBiologyFool
(99.14)
Submitted: 18/12/2009 10:49:15 :
Start Price:
$2.47
MYRX.US Score:
-31.99
Trading at less than cash and pipeline is worth more than $100 million anyway.
I'm not sure about the Javelin gamble makes much sense, but at least it didn't use cash to get it.
Recs
shastashadow
(83.26)
Submitted: 09/09/2009 22:35:46 :
Start Price:
$2.37
MYRX.US Score:
-36.12
What everyone else said
Recs
mrindependent
(75.86)
Submitted: 25/05/2010 15:52:29 :
Start Price:
$2.08
MYRX.US Score:
-11.76
Valued below cash on hand. Jumping ahead of ZZLangerhans based on his excellent may 25 blog. Going long at $4.10 prox.
Recs
SmallPimpin
(75.11)
Submitted: 26/03/2010 22:56:15 :
Start Price:
$2.37
MYRX.US Score:
-17.18
Mmm...pharmaceuticals...
Recs
Recs
biofest
(53.59)
Submitted: 06/12/2009 15:03:06 :
Start Price:
$2.82
MYRX.US Score:
-44.86
Very undevalued. Market value $130 million, cash $181 million. 3 drus in clic; 3 preclinic.
Recs
Recs
mhy729
(40.88)
Submitted: 09/09/2011 19:49:28 :
Start Price:
$1.40
MYRX.US Score:
+68.46
Lead drug candidate suspended...this is a cash play. Following the just recently announced termination of development of Azixa, there was the expected sell-off, but there wasn't a huge drop in price and it has recovered to pre-announcement levels, so it would appear that the market is being very mindful of their cash position. The remaining drugs in the pipeline aren't terribly advanced in development, and it will be interesting to see where the newly appointed CEO will take Myrexis from here.
Recs
thomasgb
(34.39)
Submitted: 13/08/2009 10:20:16 :
Start Price:
$2.44
MYRX.US Score:
-44.34
Biotech trading for less than their cash
Recs
jakethesnake9
(25.12)
Submitted: 27/07/2009 11:46:07 :
Start Price:
$2.26
MYRX.US Score:
-47.17
bought in real life at $4.50 and $4.70... definitely one of the top stocks in my real portfolio.
Recs
Recs
vaugust
(< 20)
Submitted: 07/04/2011 16:52:46 :
Start Price:
$2.20
MYRX.US Score:
+9.92
The are a buy out target
Recs
Displacement
(< 20)
Submitted: 28/09/2009 15:12:28 :
Start Price:
$3.02
MYRX.US Score:
-58.12
Taking my chances that one of their big boppers will be a winner
Recs
iddqkfyou
(< 20)
Submitted: 08/02/2010 07:32:04 :
Start Price:
$2.17
MYRX.US Score:
-19.30
I just think that 100millUSD is too low a valuation for a pipeline of potentially blockbuster drugs. Yes, they could dilute their shares away and trade for 10c eventually, but that is a 100% downside vs. a 1,000% upside.
I am fine with those odds because overall the biotech index trades upwards. I suspect that if you were to remove the post success biotechs from the index, the group would be doing even better. So invest pre-success and cast a wide net.
Recs
KMillionaire
(< 20)
Submitted: 29/12/2010 00:11:22 :
Start Price:
$2.14
MYRX.US Score:
+5.96
The pipeline looks nice, but... what do I know about these things? No debt, decent amount of cash on hand. For a speculative play on an emerging biotech, you just have to follow the trend sometimes. Looks like it's trending up, to me.
Recs
roncool11
(< 20)
Submitted: 27/05/2010 23:46:49 :
Start Price:
$2.08
MYRX.US Score:
-7.85
lots of cash
Recs
mbejar
(< 20)
Submitted: 29/08/2009 19:23:17 :
Start Price:
$2.32
MYRX.US Score:
-35.63
Company has no debt and 180millon dollars in the bank and a very intersting pipe line, that we should get some info by the end of year. The market cap is 110.20 millon and more cash than market value a no brainer
Recs
jotedr
(< 20)
Submitted: 12/05/2010 02:39:56 :
Start Price:
$2.14
MYRX.US Score:
-4.97
focus on Azixa trials
Recs
Shankapotamus
(< 20)
Submitted: 29/08/2011 00:36:05 :
Start Price:
$1.43
MYRX.US Score:
+68.11
Technically oversold with a nice balance sheet. Recent insider buys don't hurt either.
For details about CAPS-UK, and the conditions you agree to be bound by, please see our Terms and Conditions.
This page brought to you by USEQ\WEB22.
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 19 of 19